SEC Company Response from TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA, TEVJF) (CIK 0000818686) (TEVA) — Jun 18, 2014
TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA, TEVJF) (CIK 0000818686)
Date: June 18, 2014 · CIK: 0000818686 · Accession: 0000899140-14-000514
AI Filing Summary & Sentiment
File numbers found in text: 001-16174
Letter
VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Teva Pharmaceutical Industries Limited (“Teva”) Form 20-F for the Fiscal Year Ended December 31, 2013 Filed February 10, 2014 File No. 001-16174
Re:
Dear Mr. Rosenberg:
I refer to your letter to me dated June 10, 2014, containing the comment of the Staff of the Securities and Exchange Commission (“SEC”) relating to Teva’s Form 20-F for the Fiscal Year Ended December 31, 2013, and our response thereto, sent on our behalf concurrently with this letter. In connection with such response to the Staff’s comment, on behalf of Teva, I acknowledge that:
·
Teva is responsible for the adequacy and accuracy of the disclosure in its filings with the SEC;
·
Staff comments or changes to disclosure in response to Staff comments do not foreclose the SEC from taking any action with respect to the filings; and
·
Teva may not assert Staff comments as a defense in any proceeding initiated by the SEC or any person under the federal securities laws of the United States.
Very truly yours,
/s/ Eyal Desheh
Show Raw Text
CORRESP
1
filename1.htm
VIA EDGAR
June 18, 2014
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Attn: Jim B. Rosenberg, Senior Assistant Chief Accountant
Division of Corporation Finance
Re:
Teva Pharmaceutical Industries Limited (“Teva”)
Form 20-F for the Fiscal Year Ended December 31, 2013
Filed February 10, 2014
File No. 001-16174
Dear Mr. Rosenberg:
I refer to your letter to me dated June 10, 2014, containing the comment of the Staff of the Securities and Exchange Commission (“SEC”) relating to Teva’s Form 20-F for the Fiscal Year Ended December 31, 2013, and our response thereto, sent on our behalf concurrently with this letter. In connection with such response to the Staff’s comment, on behalf of Teva, I acknowledge that:
·
Teva is responsible for the adequacy and accuracy of the disclosure in its filings with the SEC;
·
Staff comments or changes to disclosure in response to Staff comments do not foreclose the SEC from taking any action with respect to the filings; and
·
Teva may not assert Staff comments as a defense in any proceeding initiated by the SEC or any person under the federal securities laws of the United States.
Very truly yours,
/s/ Eyal Desheh
Eyal Desheh
Chief Financial Officer
cc:
Mary Mast (SEC)
Christine Torney (SEC)
Richard S. Egosi (Teva)
Jeffrey S. Hochman (Willkie Farr)